Home » Stocks » IRWD

Ironwood Pharmaceuticals, Inc. (IRWD)

Stock Price: $11.83 USD 0.20 (1.72%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $11.74 -0.09 (-0.74%) Nov 27, 1:14 PM

Stock Price Chart

Key Info

Market Cap 1.89B
Revenue (ttm) 399.14M
Net Income (ttm) 110.83M
Shares Out 160.10M
EPS (ttm) 0.70
PE Ratio 16.90
Forward PE 9.47
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $11.83
Previous Close $11.63
Change ($) 0.20
Change (%) 1.72%
Day's Open 11.63
Day's Range 11.55 - 11.83
Day's Volume 535,155
52-Week Range 7.99 - 14.10

More Stats

Market Cap 1.89B
Enterprise Value 2.04B
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 160.10M
Float n/a
EPS (basic) 0.71
EPS (diluted) 0.70
FCF / Share 0.88
Dividend n/a
Dividend Yield n/a
Earnings Yield 5.92%
FCF Yield 7.41%
Payout Ratio n/a
Shares Short 20.38M
Short Ratio 8.60
Short % of Float n/a
Beta 1.40
PE Ratio 16.90
Forward PE 9.47
P/FCF Ratio 13.49
PS Ratio 4.75
PB Ratio 315.37
Revenue 399.14M
Operating Income 141.15M
Net Income 110.83M
Free Cash Flow 140.43M
Net Cash -146.82M
Net Cash / Share -0.92
Gross Margin 73.41%
Operating Margin 35.36%
Profit Margin 27.80%
FCF Margin 35.18%
ROA 21.68%
ROE n/a
ROIC 23.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 1
Overweight 0
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$11.33*
(-4.23% downside)
Low
9.00
Current: $11.83
High
14.00
Target: 11.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue42834729827415076.4422.8815065.8743.86
Revenue Growth23.59%16.21%8.88%83.18%95.66%234.06%-84.77%128.09%50.19%-
Gross Profit40831427927213250.8515.6814965.8743.86
Operating Income120-182-46.67-42.04-102-169-252-72.76-66.14-60.77
Net Income21.51-282-117-81.71-143-190-273-72.62-64.85-52.98
Shares Outstanding15615314914514213711610699.8889.65
Earnings Per Share0.14-1.85-0.78-0.56-1.00-1.39-2.35-0.68-0.65-0.59
Dividend Per Share2.29---------
Operating Cash Flow10.73-70.88-101-25.93-107-156-273-69.63-75.24-67.90
Capital Expenditures-6.921.21-2.67-3.98-3.90-3.54-9.59-13.97-9.68-17.22
Free Cash Flow3.80-69.67-103-29.92-111-159-283-83.60-84.92-85.12
Cash & Equivalents178174221313448256206176172259
Total Debt4554484924864571731790.570.660.59
Net Cash / Debt-277-273-271-173-8.6783.3526.80175171258
Assets403332606710619329279230209301
Liabilities49652859664352424124185.8699.12142
Book Value-93.25-1969.8566.7295.1388.5538.23144110160
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ironwood Pharmaceuticals, Inc.
Country United States
Employees 317
CEO Mark Mallon

Stock Information

Ticker Symbol IRWD
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: IRWD
IPO Date February 3, 2010

Description

Ironwood Pharmaceuticals, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.